{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:06:36Z","timestamp":1780380396275,"version":"3.54.1"},"reference-count":54,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Public Health Rep"],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) infection is the most common bloodborne infection in the United States. We assessed trends in HCV testing, infection, and surveillance cases among US adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used Quest Diagnostics data from 2013-2021 to assess trends in the numbers tested for HCV antibody and proportion of positivity for HCV antibody and HCV RNA. We also assessed National Notifiable Diseases Surveillance System 2013-2020 data for trends in the number and proportion of hepatitis C cases. We applied joinpoint regression for trends testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Annual HCV antibody testing increased from 1.7 million to 4.8 million from 2013 to 2021, and the positivity proportion declined (average, 0.2% per year) from 5.5% to 3.7%. The greatest percentage-point increase in HCV antibody testing occurred in hospitals and substance use disorder treatment facilities and among addiction medicine providers. HCV RNA positivity was stable at about 60% in 2013-2015 and declined to 41.0% in 2021 (2015-2021 average, \u22123.2% per year). Age-specific HCV RNA positivity was highest among people aged 40-59 years during 2013-2015 and among people aged 18-39 years during 2016-2021. The number of reported hepatitis C cases (acute and chronic) declined from 179 341 in 2015 to 105 504 in 2020 (average decline, \u221213 177 per year). The proportion of hepatitis C cases among those aged 18-39 years increased by an average of 1.4% per year during 2013-2020; among individuals aged 40-59 years, it decreased by an average of 2.3% per year during 2013-2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>HCV testing increased, suggesting improved universal screening. Various data sources are valuable for monitoring elimination progress.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00333549231224199","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:56:07Z","timestamp":1707713767000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatitis C Virus Testing, Infection, and Cases Reported Through Public Health Surveillance During Expanded Screening Recommendations, United States, 2013-2021"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-1389","authenticated-orcid":false,"given":"Kathleen N.","family":"Ly","sequence":"first","affiliation":[{"name":"Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin K.","family":"Niles","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Secaucus, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth B.","family":"Jiles","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey W.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Secaucus, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William A.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Secaucus, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola D.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"bibr1-00333549231224199","first-page":"1","volume":"40","author":"Alter MJ","year":"1991","journal-title":"MMWR Recomm Rep"},{"key":"bibr2-00333549231224199","first-page":"1","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"MMWR Recomm Rep"},{"key":"bibr3-00333549231224199","first-page":"1","volume":"61","author":"Smith BD","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"bibr4-00333549231224199","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-5-201309030-00672"},{"issue":"18","key":"bibr5-00333549231224199","first-page":"362","volume":"62","author":"Getchell JP","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr6-00333549231224199","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i28.2829"},{"key":"bibr7-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"bibr8-00333549231224199","unstructured":"US Preventive Services Task Force. Hepatitis C virus infection in adolescents and adults: screening. 2020. Accessed January 24, 2022. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/hepatitis-c-screening"},{"key":"bibr9-00333549231224199","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6902a1"},{"key":"bibr10-00333549231224199","unstructured":"American College of Obstetricians and Gynecologists. Routine hepatitis C virus screening in pregnant individuals. 2021. Accessed January 24, 2022. https:\/\/opqic.org\/acog-practice-advisory-routine-hepatitis-c-virus-screening-in-pregnant-individuals"},{"key":"bibr11-00333549231224199","unstructured":"US Department of Health and Human Services. Viral Hepatitis National Strategic Plan: A Roadmap to Elimination for the United States, 2021-2025. US Department of Health and Human Services; 2020. Accessed January 19, 2022. https:\/\/www.hhs.gov\/sites\/default\/files\/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf"},{"key":"bibr12-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance\u2014United States. 2023. https:\/\/www.cdc.gov\/hepatitis\/statistics\/SurveillanceRpts.htm"},{"key":"bibr13-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. 2022. Last reviewed June 1, 2022. Accessed May 4, 2022. https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html"},{"key":"bibr14-00333549231224199","unstructured":"Quest Diagnostics. Fact sheet. 2023. Accessed May 25, 2023. https:\/\/newsroom.questdiagnostics.com\/index.php?s=30664"},{"key":"bibr15-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2021.03.011"},{"key":"bibr16-00333549231224199","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2350"},{"key":"bibr17-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1079\/AOG.0000000000004822"},{"key":"bibr18-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Event codes & other surveillance resources. 2023. Accessed March 23, 2022. https:\/\/ndc.services.cdc.gov\/event-codes-other-surveillance-resources"},{"key":"bibr19-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13124"},{"key":"bibr20-00333549231224199","unstructured":"Centers for Disease Control and Prevention. CDC WONDER. 2023. Accessed October 27, 2023. https:\/\/wonder.cdc.gov"},{"key":"bibr21-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Hepatitis C, acute. 2020. Accessed January 24, 2022. https:\/\/ndc.services.cdc.gov\/conditions\/hepatitis-c-acute"},{"key":"bibr22-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Hepatitis C, chronic. 2020. Accessed January 24, 2022. https:\/\/ndc.services.cdc.gov\/conditions\/hepatitis-c-chronic"},{"key":"bibr23-00333549231224199","unstructured":"Joinpoint Trend Analysis Software. Version 4.9.0.0. Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute; March 2021."},{"key":"bibr24-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Hepatitis C surveillance guidance. July 17, 2023. Accessed May 4, 2022. https:\/\/www.cdc.gov\/hepatitis\/statistics\/surveillanceguidance\/HepatitisC.htm"},{"key":"bibr25-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1177\/00333549231170044"},{"key":"bibr26-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Electronic case reporting (eCR). 2022. Accessed September 21, 2022. https:\/\/www.cdc.gov\/ecr\/index.html"},{"key":"bibr27-00333549231224199","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6914a2"},{"key":"bibr28-00333549231224199","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6528a2"},{"key":"bibr29-00333549231224199","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.S6-A.2"},{"issue":"2","key":"bibr30-00333549231224199","first-page":"147","volume":"49","author":"Bertakis KD","year":"2000","journal-title":"J Fam Pract"},{"key":"bibr31-00333549231224199","unstructured":"Substance Abuse and Mental Health Services Administration. 2021 National Survey on Drug Use and Health (NSDUH) releases. 2021. Accessed May 19, 2023. https:\/\/www.samhsa.gov\/data\/release\/2021-national-survey-drug-use-and-health-nsduh-releases#annual-national-report"},{"key":"bibr32-00333549231224199","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2023. Updated February 15, 2023. Accessed March 23, 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"bibr33-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13060"},{"key":"bibr34-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13343"},{"issue":"17","key":"bibr35-00333549231224199","first-page":"459","volume":"64","author":"Coyle C","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr36-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2019.101036"},{"key":"bibr37-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13182"},{"key":"bibr38-00333549231224199","unstructured":"Tennessee Department of Health. End the syndemic Tennessee. 2022. Accessed May 9, 2022. https:\/\/endthesyndemictn.org"},{"key":"bibr39-00333549231224199","unstructured":"California Department of Public Health. Ending the epidemics: addressing human immunodeficiency virus (HIV), hepatitis C virus (HCV), and sexually transmitted infections (STIs) in California: integrated statewide strategic plan overview 2022-2026. 2022. Accessed May 9, 2022. https:\/\/www.cdph.ca.gov\/Programs\/CID\/DOA\/CDPH%20Document%20Library\/CDPH_StratPlan2021_FINAL_ADA.pdf?msclkid=2f554afccfd411ec90b0fdbcc7f13a1f"},{"key":"bibr40-00333549231224199","unstructured":"Washington State Department of Health. Hep C Free Washington: plan to eliminate hepatitis C in Washington State by 2030. 2019. Accessed May 9, 2022. https:\/\/doh.wa.gov\/sites\/default\/files\/legacy\/Documents\/Pubs\/\/150nonDOH-HepCFreeWA-PlanJuly2019.pdf?uid=627974f142b57"},{"key":"bibr41-00333549231224199","unstructured":"University of New Mexico. Project ECHO. 2023. Accessed May 9, 2022. https:\/\/hsc.unm.edu\/echo"},{"key":"bibr42-00333549231224199","unstructured":"O\u2019Neill Institute for National and Global Health Law at Georgetown University Law Center, National Viral Hepatitis Roundtable, Center for Health Law & Policy Innovation at Harvard Law School. Hep ElimiNATION: a national evaluation of states\u2019 capacity for viral hepatitis elimination. 2023. Accessed March 22, 2022. https:\/\/eliminatehep.org\/about"},{"key":"bibr43-00333549231224199","unstructured":"National Viral Hepatitis Roundtable. Hepatitis C state of Medicaid access. 2023. Accessed June 14, 2023. https:\/\/stateofhepc.org"},{"key":"bibr44-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu509"},{"key":"bibr45-00333549231224199","unstructured":"Centers for Disease Control and Prevention. HIV, viral hepatitis, STD, and TB quality measures. 2023. Last reviewed February 21, 2023. Accessed March 23, 2022. https:\/\/www.cdc.gov\/nchhstp\/highqualitycare\/quality-measures.html#quality-measures"},{"key":"bibr46-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.01.031"},{"key":"bibr47-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Hepatitis C, perinatal infection 2018 case definition. 2021. Accessed August 8, 2022. https:\/\/ndc.services.cdc.gov\/case-definitions\/hepatitis-c-perinatal-infection-2018"},{"key":"bibr48-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac139"},{"key":"bibr49-00333549231224199","first-page":"1","volume":"52","author":"Alter MJ","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"bibr50-00333549231224199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.01.007"},{"key":"bibr51-00333549231224199","unstructured":"Council of State and Territorial Epidemiologists. Addressing Gaps in Public Health Reporting of Race and Ethnicity Data for COVID-19: Findings & Recommendations Among 45 State & Local Health Departments. Centers for Disease Control and Prevention; 2022. Accessed July 25, 2022. https:\/\/preparedness.cste.org\/wp-content\/uploads\/2022\/04\/RaceEthnicityData_FINAL.pdf"},{"key":"bibr52-00333549231224199","unstructured":"James CV, Lyons B, Synisch PA, Scholle SH. Modernizing race and ethnicity data in our federal health programs. Blog post. The Commonwealth Fund. October 26, 2021. Accessed July 25, 2022. https:\/\/www.commonwealthfund.org\/blog\/2021\/modernizing-race-and-ethnicity-data-our-federal-health-programs"},{"key":"bibr53-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Integrated viral hepatitis surveillance and prevention funding for health departments. 2021. Last reviewed April 24, 2023. Accessed March 22, 2022. https:\/\/www.cdc.gov\/hepatitis\/policy\/2103_CoAg.htm"},{"key":"bibr54-00333549231224199","unstructured":"Centers for Disease Control and Prevention. Data Modernization Initiative strategic implementation plan. 2021. Accessed August 8, 2022. https:\/\/www.cdc.gov\/surveillance\/pdfs\/FINAL-DMI-Implementation-Strategic-Plan-12-22-21.pdf"}],"container-title":["Public Health Reports\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00333549231224199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00333549231224199","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00333549231224199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:39:30Z","timestamp":1777628370000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00333549231224199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":54,"alternative-id":["10.1177\/00333549231224199"],"URL":"https:\/\/doi.org\/10.1177\/00333549231224199","relation":{},"ISSN":["0033-3549","1468-2877"],"issn-type":[{"value":"0033-3549","type":"print"},{"value":"1468-2877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"article-number":"00333549231224199"}}